Drugs for acid related disorders - versus control - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

conversion to SARS-CoV- 2–positive status via NP swab 0.85 [0.25, 2.88]< 192%2 studies (-/2)60.6 %NAnot evaluable important-
new illness compatible with Covid-19 2.79 [1.65, 4.70]< 194%2 studies (-/2)0.0 %seriousnot evaluable lowimportant-
symptomatic Covid-19 0.88 [0.80, 0.97]< 10%2 studies (-/2)99.6 %criticalnot evaluable very lowimportant-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.